Media headlines about Antares Pharma (NASDAQ:ATRS) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Antares Pharma earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 44.9704260902065 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- $14.80 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter (americanbankingnews.com)
- INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Antares Pharma, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 22, 2017 – ATRS (feeds.benzinga.com)
- ATRS LOSS NOTICE: Rosen Law Firm Reminds Antares Pharma, Inc. Investors of Important Deadline in Class Action (finance.yahoo.com)
- Glancy Prongay & Murray LLP Commences Investigation on Behalf of Antares Pharma, Inc. Investors (ATRS) (markets.financialcontent.com)
ATRS has been the topic of a number of analyst reports. HC Wainwright set a $5.00 price objective on shares of Antares Pharma and gave the company a “buy” rating in a report on Wednesday, August 9th. Piper Jaffray Companies reiterated a “buy” rating on shares of Antares Pharma in a research note on Friday, September 8th. Finally, ValuEngine lowered shares of Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and two have given a strong buy rating to the stock. Antares Pharma has an average rating of “Buy” and an average target price of $3.84.
Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The firm had revenue of $15.10 million for the quarter, compared to analyst estimates of $14.01 million. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year. analysts expect that Antares Pharma will post -0.11 earnings per share for the current year.
In related news, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Leonard S. Jacob sold 230,000 shares of Antares Pharma stock in a transaction on Monday, October 9th. The stock was sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. 11.60% of the stock is owned by company insiders.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.